HS: Targeted Therapies and Training May Improve Patient Quality of Life

Chronic, non-communicable inflammatory skin diseases encompass a diverse group of conditions affecting a substantial portion of the global population, with estimates ranging from 20%–25%. Some of the most prevalent chronic inflammatory skin disorders include atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa (HS). HS can significantly impact quality of life and is associated with various comorbidities, making its early diagnosis and proper management crucial. Despite significant advancements in diagnosis and treatment, challenges persist, particularly in recognizing and addressing rarer conditions due to low awareness and diagnostic tools, according to a study published in Frontiers in Medicine.

Treatment strategies often involve systemic immunosuppression, although issues like adverse effects, inadequate therapeutic responses, and relapses pose ongoing challenges. However, diagnostic delays are common, increasing disease severity and concomitant conditions. Diagnosing HS relies on physical examination and medical history evaluation, and there is a pressing need for improved diagnostic tools.

HS treatment encompasses pharmacological and surgical options, with systemic treatment limited in scope. Adalimumab, an anti-TNF-a antibody, is the sole approved systemic treatment for HS. However, given the complexity of the disease's pathogenesis, the development of effective targeted therapies has been hindered. Ongoing clinical trials focus on new systemic pharmacological approaches, yet these efforts often lack a comprehensive understanding of the underlying mechanisms. "Training of doctors such as general physicians, dermatologists, surgeons, and gynecologists, as well as programs to raise/create the awareness of the disease within large parts of the society are needed.," said researchers.

A multi-pronged approach is necessary to address the challenges posed by HS and other chronic inflammatory skin diseases. Increasing awareness among healthcare professionals and the general public is crucial for early detection and intervention. Alongside this, research efforts must strive to unravel the intricate molecular and immunological processes driving these diseases. Such insights can pave the way for developing targeted therapies that can transform the landscape of treatment options. Additionally, a holistic approach that considers both physical and psychological aspects of patient care and lifestyle modifications will contribute to more comprehensive and effective management strategies.

Chronic, non-communicable inflammatory skin diseases are a global health concern, affecting millions of individuals. Despite the complex array of causative factors, HS is just one of many inflammatory skin diseases that advancements in diagnosis and treatment have been significant. Yet, issues are still related to awareness, diagnostics, and treatment responses.

"With ongoing research, enhanced awareness, and the development of targeted therapies, it is anticipated that the future will bring improved outcomes and better quality of life for individuals living with these chronic inflammatory skin diseases," said researchers.

Reference

Ujiie H, Rosmarin D, Schön MP, et al. Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Frontiers in Medicine. 2022;9. doi:10.3389/fmed.2022.875492